Wilson L - Search Results

1

The Patient Perspective: Putting the Patient at the Center of the Translational Innovation Process.

Wilson L, Lin L, Singh K. Wilson L, et al. Clin Pharmacol Ther. 2020 Jan;107(1):82-84. doi: 10.1002/cpt.1686. Epub 2019 Nov 23. Clin Pharmacol Ther. 2020. PMID: 31758800 Free PMC article.

2

Use and Costs of Medical Foods and Convenience-Packaged Drugs in the California Workers' Compensation System.

Lin TK, Wilson L. Lin TK, et al. Among authors: wilson l. J Manag Care Spec Pharm. 2018 Aug;24(8):819-833. doi: 10.18553/jmcp.2018.24.8.819. J Manag Care Spec Pharm. 2018. PMID: 30058988 Free PMC article.

3

Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.

Wilson L, Lin T, Wang L, Patel T, Tran D, Kim S, Dacey K, Yuen C, Kroon L, Brodowy B, Rodondi K. Wilson L, et al. J Manag Care Spec Pharm. 2017 Feb;23(2):163-169. doi: 10.18553/jmcp.2017.23.2.163. J Manag Care Spec Pharm. 2017. PMID: 28125363 Free PMC article.

4

Giving Patients a Meaningful Voice in United States Regulatory Decision Making: The Role for Health Preference Research.

Johnson FR, Beusterien K, Özdemir S, Wilson L. Johnson FR, et al. Among authors: wilson l. Patient. 2017 Aug;10(4):523-526. doi: 10.1007/s40271-017-0250-z. Patient. 2017. PMID: 28597374 No abstract available.

5

Biologic excipients: Importance of clinical awareness of inactive ingredients.

Ionova Y, Wilson L. Ionova Y, et al. Among authors: wilson l. PLoS One. 2020 Jun 25;15(6):e0235076. doi: 10.1371/journal.pone.0235076. eCollection 2020. PLoS One. 2020. PMID: 32584876 Free PMC article. Review.

6

Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.

Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L. Ting J, et al. Among authors: wilson l. Value Health. 2015 Sep;18(6):774-82. doi: 10.1016/j.jval.2015.04.008. Epub 2015 Jun 22. Value Health. 2015. PMID: 26409604 Free article.

7

Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.

Wilson L, Huang W, Chen L, Ting J, Cao V. Wilson L, et al. Thyroid. 2017 Aug;27(8):1043-1052. doi: 10.1089/thy.2016.0572. Epub 2017 Jun 7. Thyroid. 2017. PMID: 28486081

8

Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry.

Jeong CW, Cowan JE, Broering JM, Ten Ham RMT, Wilson LS, Carroll PR, Cooperberg MR. Jeong CW, et al. Eur Urol. 2019 Dec;76(6):743-751. doi: 10.1016/j.eururo.2019.07.012. Epub 2019 Jul 23. Eur Urol. 2019. PMID: 31345635

9

A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.

Chan A, Dang C, Wisniewski J, Weng X, Hynson E, Zhong L, Wilson L. Chan A, et al. Among authors: wilson l. Am J Clin Oncol. 2022 Feb 1;45(2):66-73. doi: 10.1097/COC.0000000000000884. Am J Clin Oncol. 2022. PMID: 34991104

10

Patient Preference Trade-offs for Next-Generation Kidney Replacement Therapies.

Wilson L, Gress AF, Frassetto L, Sarathy H, Gress EA, Fissell WH, Roy S. Wilson L, et al. Clin J Am Soc Nephrol. 2024 Jan 1;19(1):76-84. doi: 10.2215/CJN.0000000000000313. Epub 2023 Oct 6. Clin J Am Soc Nephrol. 2024. PMID: 37874941 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,123 results

Search Page

Filters